Compare Hershey Co (HSY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs BIO-TECHNE Corp — how do they compare? Hershey Co trades at $171.66 (market cap $34.83B), while BIO-TECHNE Corp trades at $71.52 (market cap $11.16B). The key difference: Hershey Co is far larger — about 3.1× BIO-TECHNE Corp's market cap, and Hershey Co pays the higher dividend (3.38%). Which is the better fit depends on your goals.
| HSY | TECH | |
|---|---|---|
Market Cap | $34.83B | $11.16B |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $72.12 |
52-Week Low | $162.31 | $43.31 |
Enterprise Value | $39.63B | $11.24B |
Dividend Yield | 3.38% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $171.72, showing modest daily gains of 0.18%. The stock faces bearish technical signals with recent price action near support at $170, while fundamentals reveal mixed performance with strong earnings beats but compressed margins. Recent Q1 2026 EPS of $2.35 exceeded expectations by 15%, though net income margin declined to 7.55% in 2025 from 19.82% in 2024 due to cocoa cost pressures. The company maintains solid cash flow generation with $2.28B operating cash flow in 2025.
Hershey presents a cautious opportunity as margin recovery begins in Q2 2026, with analyst consensus target of $208.42 offering 21% upside. However, volume concerns and competitive pressures pose near-term risks. The 3.3% dividend yield provides income support while investors await evidence of sustained sales volume recovery and margin expansion in upcoming earnings.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
